Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology.

[1]  J. Jonas,et al.  Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration. , 2006, American journal of ophthalmology.

[2]  Charles Bonnet syndrome (visual hallucinations) after intravitreal avastin injection for age-related macular degeneration. , 2007, American journal of ophthalmology.

[3]  Jennifer A. Web.  Genentech decision expands access to bevacizumab , 2008 .

[4]  P. Rosenfeld,et al.  Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. , 2006, Ophthalmology.

[5]  R. Avery,et al.  Intravitreal bevacizumab. Authors' reply , 2007 .

[6]  A. Schakal,et al.  Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. , 2007, Archives of ophthalmology.

[7]  Lawrence A. Yannuzzi,et al.  PRECLINICAL AND PHASE 1A CLINICAL EVALUATION OF AN ANTI-VEGF PEGYLATED APTAMER (EYE001) FOR THE TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION , 2002, Retina.

[8]  J Katz,et al.  Racial differences in the cause-specific prevalence of blindness in east Baltimore. , 1991, The New England journal of medicine.

[9]  Philip J Rosenfeld,et al.  Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. , 2005, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[10]  P. Campochiaro,et al.  A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. , 2006, Ophthalmology.

[11]  M. Hughes,et al.  Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. , 2006, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[12]  Emmett T. Cunningham,et al.  VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION CLINICAL TRIAL GROUP. PEGAPTANIB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2004 .

[13]  Richard F Spaide,et al.  INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[14]  J. Monés,et al.  Extrafoveal choroidal neovascularization secondary to wet age-related macular degeneration treated with intravitreal bevacizumab. , 2007, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[15]  M. Blumenkranz,et al.  RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2007, Retina.

[16]  N. Gabrić,et al.  Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.

[17]  N. Gabrić,et al.  Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. , 2007, Ophthalmology.

[18]  Gary C. Brown,et al.  A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. , 2008, Ophthalmology.

[19]  Philip J Rosenfeld,et al.  Ranibizumab: Phase III clinical trial results. , 2006, Ophthalmology clinics of North America.

[20]  R S Nickerson,et al.  The Framingham Eye Study. I. Outline and major prevalence findings. , 1977, American journal of epidemiology.

[21]  Benita J. O’Colmain,et al.  Prevalence of age-related macular degeneration in the United States. , 2004, Archives of ophthalmology.

[22]  F. Ferris,et al.  Age-related macular degeneration and blindness due to neovascular maculopathy. , 1984, Archives of ophthalmology.

[23]  P. Rosenfeld,et al.  The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide , 2006, British Journal of Ophthalmology.

[24]  L. Damico,et al.  DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[25]  Peter K. Kaiser,et al.  ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006 .

[26]  P. Rosenfeld,et al.  Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. , 2005, Ophthalmology.

[27]  M. Maia,et al.  Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES) , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[28]  M. Larsen,et al.  Treatment of choroidal neovascularization using intravitreal bevacizumab. , 2007, Acta ophthalmologica Scandinavica.

[29]  S. Garg,et al.  Retinal pigment epithelial tear after intravitreal bevacizumab injection. , 2006, American journal of ophthalmology.

[30]  C. Regillo,et al.  Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. , 2008, American journal of ophthalmology.

[31]  R. Klein,et al.  Prevalence of age-related maculopathy. The Beaver Dam Eye Study. , 1992, Ophthalmology.

[32]  I. Scott,et al.  Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. , 2006, Investigative ophthalmology & visual science.

[33]  Peter K Kaiser,et al.  Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. , 2007, Ophthalmology.

[34]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[35]  K. Bartz-Schmidt,et al.  Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[36]  Manju Patel,et al.  Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. , 2006, Ophthalmology.

[37]  J. Vander,et al.  Verteporfin Therapy and Intravitreal Bevacizumab Combined and Alone in Choroidal Neovascularization due to Age-Related Macular Degeneration , 2008 .

[38]  P. Rosenfeld,et al.  Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. , 2006, Ophthalmology.

[39]  K. Bartz-Schmidt,et al.  Does intravitreal injection of bevacizumab have an effect on the blood-aqueus barrier function? , 2006, British Journal of Ophthalmology.

[40]  A. Adamis,et al.  Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. , 2007, Ophthalmology.

[41]  P. Rosenfeld,et al.  Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. , 2005, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[42]  R. Maturi,et al.  ELECTROPHYSIOLOGIC FINDINGS AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT , 2006, Retina.

[43]  J. Vander,et al.  INTRAVITREAL BEVACIZUMAB FOR REFRACTORY PIGMENT EPITHELIAL DETACHMENT WITH OCCULT CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION , 2007, Retina.

[44]  I. Perlman,et al.  ELECTROPHYSIOLOGIC AND RETINAL PENETRATION STUDIES FOLLOWING INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN) , 2006, Retina.

[45]  A. Lotery,et al.  Retinal pigment epithelial tear following intravitreal bevacizumab for choroidal neovascular membrane due to age-related macular degeneration , 2007, British Journal of Ophthalmology.

[46]  M. Farah,et al.  Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[47]  D. Guyer,et al.  Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. , 2006, Ophthalmology.

[48]  J. Pulido,et al.  Pharmacokinetics of intravitreal ranibizumab (Lucentis). , 2007, Ophthalmology.

[49]  P. Rosenfeld,et al.  Dr. Rosenfeld and colleagues reply [13] , 2007 .

[50]  J. Vander.  Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration , 2007 .

[51]  G. Peyman,et al.  TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN) , 2006, Retina.

[52]  A. Bazarbachi,et al.  Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. , 2006, American journal of ophthalmology.

[53]  J. Jonas,et al.  Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. , 2007, Acta ophthalmologica Scandinavica.

[54]  T. Wong,et al.  Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. , 2007, American journal of ophthalmology.

[55]  D. Sarraf,et al.  TEARS OF THE RETINAL PIGMENT EPITHELIUM: An Old Problem in a New Era , 2007, Retina.

[56]  P. L. Hildebrand,et al.  Preferred practice patterns. , 1996, Ophthalmology.

[57]  R. Tibrewala,et al.  VISUAL IMPROVEMENT FOLLOWING INTRAVITREAL BEVACIZUMAB (AVASTIN) IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[58]  Sander R. Dubovy,et al.  SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[59]  George A. Williams,et al.  TREATMENT OF NAÏVE LESIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PEGAPTANIB , 2007, Retina.

[60]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[61]  R. Klein,et al.  Cataracts and macular degeneration in older Americans. , 1982, Archives of ophthalmology.

[62]  J. Raftery,et al.  Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness , 2007, British Journal of Ophthalmology.

[63]  S. Russell,et al.  Vitreous injections of pegaptanib sodium triggering allergic reactions. , 2007, American journal of ophthalmology.

[64]  R. Bhisitkul.  Vascular endothelial growth factor biology: clinical implications for ocular treatments , 2006, British Journal of Ophthalmology.

[65]  G. Melo,et al.  Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. , 2006, Acta ophthalmologica Scandinavica.

[66]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[67]  T. Wong,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2007, New England Journal of Medicine.

[68]  S. Mennel,et al.  Visual hallucinations after intravitreal injection of bevacizumab in vascular age-related macular degeneration. , 2007, American journal of ophthalmology.

[69]  I. Scott,et al.  Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study) , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[70]  W. Freeman,et al.  STANDARDIZED VISUAL ACUITY RESULTS ASSOCIATED WITH PRIMARY VERSUS SECONDARY BEVACIZUMAB (AVASTIN) TREATMENT FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION , 2007, Retina.

[71]  U. Schmidt-Erfurth,et al.  EVALUATION OF ANTERIOR CHAMBER INFLAMMATORY ACTIVITY IN EYES TREATED WITH INTRAVITREAL BEVACIZUMAB , 2006, Retina.

[72]  A. L. Höfling-Lima,et al.  Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection , 2007, Eye.

[73]  T. Lai,et al.  Retinal pigment epithelial tear following intravitreal ranibizumab injections for neovascular age-related macular degeneration , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[74]  A. Augustin,et al.  TRIPLE THERAPY FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION: Verteporfin PDT, Bevacizumab, and Dexamethasone , 2007, Retina.

[75]  S. Bakri,et al.  Retinal pigment epithelial tear after intravitreal ranibizumab. , 2007, American journal of ophthalmology.

[76]  Cherylyn Beckey,et al.  Pegaptanib: A Novel Approach to Ocular Neovascularization , 2006, The Annals of pharmacotherapy.

[77]  J. Jonas,et al.  Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. , 2007, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[78]  M. C. Donati,et al.  Intravitreal Bevacizumab Therapy for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: 6-Month Results of an Open-Label Uncontrolled Clinical Study , 2007, European journal of ophthalmology.

[79]  Gerald Liew,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.

[80]  H. Quiroz-Mercado,et al.  Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[81]  P. Kaiser,et al.  RETINAL PIGMENT EPITHELIAL TEARS AFTER INTRAVITREAL BEVACIZUMAB INJECTION FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2007, Retina.

[82]  William J Feuer,et al.  An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. , 2007, American journal of ophthalmology.

[83]  M. Blumenkranz,et al.  Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. , 2005, Ophthalmology.

[84]  Arthur D. Fu,et al.  INTRAVITREAL BEVACIZUMAB FOR PREVIOUSLY TREATED CHOROIDAL NEOVASCULARIZATION FROM AGE-RELATED MACULAR DEGENERATION , 2007, Retina.

[85]  J. Vander,et al.  Ranibizumab for Predominantly Classic Neovascular Age-related Macular Degeneration: Subgroup Analysis of First-year ANCHOR Results , 2008 .

[86]  T. Ciulla,et al.  Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. , 2006, Archives of ophthalmology.

[87]  K. Eng,et al.  Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.

[88]  David J. Wilson,et al.  INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2007, Retina.

[89]  J. P. Sy,et al.  Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. , 2006, Ophthalmology.

[90]  J. Vander,et al.  Subgroup Analysis of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration , 2008 .